Severe malaria is a life-threatening complication of Plasmodium falciparum infection, requiring urgent medical intervention. It is characterized by vital organ dysfunction and high mortality if untreated, necessitating rapid diagnosis and aggressive treatment in a hospital setting.
🦟 Overview and Pathophysiology
Severe malaria results from P. falciparum sequestration in microvasculature, leading to organ failure:
Causes
- Species: Primarily P. falciparum
- Mechanism: Cytoadherence and rosetting of infected red blood cells
- Risk Factors: Delayed treatment, non-immune individuals, pregnancy
🔍 Clinical Presentation
Severe malaria presents with systemic instability and organ-specific signs:
Symptoms
General: Persistent fever, prostration, severe weakness
Neurological: Confusion, seizures, coma
Respiratory: Shortness of breath, respiratory distress
Signs
Vital: Hypotension, tachycardia
Neurological: Glasgow Coma Scale <11, abnormal posturing
Hematologic: Severe pallor, bleeding tendencies
Renal: Reduced urine output
- Cerebral malaria (unrousable coma)
- Severe anemia (Hb <5 g/dL in children, <7 g/dL in adults)
- Respiratory distress (acidotic breathing)
- Hypoglycemia (<2.2 mmol/L)
- Renal failure (serum creatinine >265 µmol/L)
- Shock (systolic BP <80 mmHg in adults)
🧪 Diagnosis
Rapid confirmation is critical due to high mortality risk:
Investigations
First-Line: Rapid Diagnostic Test (RDT) and microscopy (parasitemia >2-5%)
Blood Tests: Full Blood Count, glucose, renal/liver function, blood gases
Imaging: Consider CT/MRI if cerebral involvement suspected
Supportive: Blood culture to rule out sepsis
💊 Treatment
Immediate parenteral therapy and supportive care are essential.
Non-Pharmacological
Oxygen therapy, IV fluids, cooling for hyperthermia, nursing in semi-prone position.
Artesunate (IV)
- Dose: 2.4 mg/kg IV at 0, 12, 24 hours, then daily
- Route: Intravenous (preferred)
- Duration: Until oral therapy possible (minimum 24 hours)
- Evidence: [A] - First-line per WHO/Ghana guidelines
Artemether (IM)
- Dose: 3.2 mg/kg IM on Day 1, then 1.6 mg/kg daily
- Route: Intramuscular (alternative if IV unavailable)
- Duration: Until oral therapy possible
- Key Point: Less preferred than artesunate
Quinine (IV)
- Dose: 20 mg/kg loading dose over 4 hours, then 10 mg/kg 8-hourly
- Route: Intravenous
- Duration: Until oral therapy possible; monitor for hypoglycemia
- Contraindications: Avoid loading dose if quinine already given
Follow-Up Oral Therapy
Regimen: Artemether-Lumefantrine (AL) or Artesunate-Amodiaquine (AS+AQ) for 3 days after parenteral therapy
Key Point: Complete course to prevent recrudescence
- Blood transfusion for severe anemia (Hb <5 g/dL)
- Dextrose 10% IV for hypoglycemia
- Anticonvulsants (e.g., diazepam 0.15 mg/kg IV) for seizures
- Renal replacement therapy if acute kidney injury persists
🤰 Special Populations: Pregnancy
Pregnancy increases risk; manage in intensive care if possible.
All Trimesters
Preferred: Artesunate IV (as above)
Alternative: Quinine IV + Clindamycin (if artesunate unavailable)
Support: Fetal monitoring, magnesium sulfate if eclampsia suspected
🚨 Referral and Monitoring
- Admit to hospital with ICU capability
- Continuous monitoring of vital signs, GCS, and parasitemia
- Refer to tertiary center if complications (e.g., cerebral malaria) not manageable locally
Initiate treatment before transfer; delay worsens prognosis.
🧠 Key Takeaways
- ✅ Urgent Diagnosis: RDT/microscopy; treat immediately if positive
- ✅ Parenteral First-Line: Artesunate IV preferred
- ✅ Supportive Care: Transfusion, glucose, anticonvulsants as needed
- ✅
:Pregnancy: Artesunate or quinine; ICU if possible - ✅ Monitor Closely: Vital signs, organ function, response to therapy
- ✅ Refer Early: For complications or lack of improvement